VivoSeq
Cardiovascular

Percutaneous Coronary Intervention (PCI)

0

Pipeline Programs↗

0

Active Trials↗

7

Companies Involved↗

Percutaneous Coronary Intervention (PCI) is an early-stage landscape with 0 programs across 7 companies. The most active players are Eli Lilly, Tanabe Pharma Corporation, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

0 programs

PreclinicalTanabe Pharma Corporation logo

Tanabe Pharma Corporation

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalGilead logo

Gilead

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Completed15 · 68%
Unknown status4 · 18%
Terminated2 · 9%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

22 trials

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00059215·905 enrolled
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
Completed·UUniversity of Patras·Phase 4·NCT01463150·27 enrolled
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 2·NCT00508924·140 enrolled
Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients
Completed·TToujinkai Hospital·N/A·NCT00848562·129 enrolled
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
Completed·Novartis logoNovartis·Phase 3·NCT01156571·11,145 enrolled
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Completed·Gilead logoGilead·Phase 3·NCT01442038·2,651 enrolled
Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)
Completed·OOttawa Heart Institute Research Corporation·Phase 3·NCT00251823·400 enrolled
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).
Completed·UUniversity of Patras·Phase 3·NCT01109784·70 enrolled
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT01347580·1,875 enrolled
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT01103440·36 enrolled
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
Completed·Sanofi logoSanofi·Phase 2/3·NCT00077844·3,532 enrolled
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
Completed·AAblynx, a Sanofi company·Phase 2·NCT01020383·364 enrolled
Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
Completed·CCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal·Phase 3·NCT00693069·120 enrolled
Randomized Multicenter Trial of Prehospital Initiated Facilitated Percutaneous Coronary Intervention (PCI) Versus Primary PCI in ST-segment-Elevation MI (STEMI)
Completed·—·Phase 4·NCT00359918·162 enrolled
Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)
Completed·—·Phase 1/2·NCT01179776·16 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)